The Emirates Drug Establishment (EDE) has approved Wegovy (semaglutide), an oral once-daily treatment indicated for long-term weight management in adults living with obesity or overweight associated with weight-related medical conditions.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
